Placebo 100mg

DRUG3 trials

Sponsors

Federal University of the Valleys of Jequitinhonha and Mucuri, University College, London, Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Conditions

Blood PressureBreast CancerCancerColorectal CancerDental AnxietyGastro-oesophageal CancerHeart RateNonalcoholic Steatohepatitis (NASH)

Phase 1

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

CompletedNCT03392779

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Nonalcoholic Steatohepatitis (NASH)

Start: 2018-01-05End: 2019-03-22Updated: 2019-08-13

Phase 3

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

Active, not recruitingNCT02804815

University College, LondonBreast Cancer, Cancer, Colorectal Cancer +2

Start: 2015-10-31End: 2026-10-31Target: 11000Updated: 2025-06-10

Unknown Phase

Valerian for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery

CompletedNCT01612130

Federal University of the Valleys of Jequitinhonha and MucuriBlood Pressure, Dental Anxiety, Heart Rate

Start: 2003-03-31End: 2003-08-31Updated: 2012-06-06

Related Papers

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Expert Opinion on Investigational Drugs2021-03-086 citations